The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19 DOI Open Access
Ali Attiq, Lui Jin Yao, Sheryar Afzal

и другие.

International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108255 - 108255

Опубликована: Окт. 16, 2021

Язык: Английский

Vasculopathy in COVID-19 DOI Open Access
Robert Flaumenhaft,

Keiichi Enjyoji,

Alec A. Schmaier

и другие.

Blood, Год журнала: 2022, Номер 140(3), С. 222 - 235

Опубликована: Янв. 5, 2022

Язык: Английский

Процитировано

98

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets DOI
Krishna Sriram, Paul A. Insel

Physiological Reviews, Год журнала: 2020, Номер 101(2), С. 545 - 567

Опубликована: Окт. 30, 2020

Evolving information has identified disease mechanisms and dysregulation of host biology that might be targeted therapeutically in coronavirus 2019 (COVID-19). Thrombosis coagulopathy, associated with pulmonary injury inflammation, are emerging clinical features COVID-19. We present a framework for thrombosis COVID-19 initially derive from interaction SARS-CoV-2 ACE2, resulting angiotensin signaling subsequent inflammation tissue injury. These responses result increased by thrombin (proteinase-activated) purinergic receptors, which promote platelet activation exert pathological effects on other cell types (e.g., endothelial cells, epithelial fibroblasts), further enhancing Inhibitors receptors may, thus, have therapeutic blunting platelet-mediated thromboinflammation dysfunction types. Such inhibitors include agents anti-platelet drugs) approved indications, could repurposed to treat, potentially improve the outcome of, patients. COVID-19, caused virus, drives signaling, which, turn, increases thrombin-mediated purinergic-mediated platelets increase inflammation. This impacts lungs can also systemic effects. drive or coagulation cascade provide opportunities treat thromboinflammation.

Язык: Английский

Процитировано

101

The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation DOI Creative Commons
Sam Kant, Steven Menez,

Mohamed Hanouneh

и другие.

BMC Nephrology, Год журнала: 2020, Номер 21(1)

Опубликована: Окт. 27, 2020

Abstract The pandemic of coronavirus disease 2019 (CoVID-19) has been an unprecedented period. afflicts multiple organ systems, with acute kidney injury (AKI) a major complication in seriously ill patients. incidence AKI patients CoVID-19 is variable across numerous international studies, but the high and its associated worse outcomes critical care setting are consistent finding. A multitude patterns mechanisms have elucidated, novel strategies to address shortage renal replacement therapy equipment implemented. also had consequences on longitudinal management chronic end stage disease. Kidney transplant recipients may be especially susceptible as result immunosuppression, preliminary studies demonstrating mortality rates. Increased surveillance low threshold for testing adjustment immunosuppression regimen during periods illness recommended.

Язык: Английский

Процитировано

100

Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication DOI Creative Commons

Shuba Krishnan,

Hampus Nordqvist,

Anoop T. Ambikan

и другие.

Molecular & Cellular Proteomics, Год журнала: 2021, Номер 20, С. 100159 - 100159

Опубликована: Янв. 1, 2021

Язык: Английский

Процитировано

100

The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19 DOI Open Access
Ali Attiq, Lui Jin Yao, Sheryar Afzal

и другие.

International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108255 - 108255

Опубликована: Окт. 16, 2021

Язык: Английский

Процитировано

83